Oklo Stock: Site Progress but the Same Dilution Trap

Oklo filed new site license applications with the NRC this quarter, and the Department of Energy expanded its advanced reactor demonstration program. The stock initially rallied on the news, then gave back most of the gain. Some conditions have softened since the December sell call. The ones that drove that call have not.

The December downgrade rested on two structural issues: a valuation that assumed a smooth regulatory path, and a share count that rose with each financing round. A third condition – a revenue start date that kept moving further out – compounded the first two. Those three formed a risk stack that made the payoff negative.

Since December, Oklo submitted applications for two new sites and the DOE added funding for advanced reactor development. These are real steps forward. They do not shorten the NRC review timeline for the initial site license. Oklo needs that license before it can sell a single megawatt-hour. The NRC has never completed a Part 52 licensing review for a commercial advanced reactor. That means the review duration is a known unknown.

Each quarter of delay pushes first revenue out by a quarter. The company finances operations through equity offerings. A longer timeline means more shares outstanding when revenue finally arrives. The cost of that dilution compounds with every quarter of NRC review. The current stock price does not reflect that compounding.

The simple read is that the stock is cheaper than December highs and now has more news flow. The better read is that the regulatory timeline has no historical precedent for speed. Every favorable announcement so far has lifted the stock, then the market repriced when the next milestone took longer than expected. That pattern rewards selling into rallies, not buying dips.

Oklo has not yet submitted a final safety analysis report. The NRC expects site application reviews to run 18 to 24 months. The initial site application landed in early 2025.